Tirzepatide
Dual GIP/GLP-1 agonist: weight & glucose control
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Related comparisons
Semaglutide vs Tirzepatide vs RetatrutideWHAT IS TIRZEPATIDE?
Detailed overview
Tirzepatide (Mounjaro / Zepbound, LY3298176) is Eli Lilly's first dual GIP/GLP-1 receptor agonist, developed and approved for type 2 diabetes and obesity. The SURPASS and SURMOUNT trials reported an average 26.6% body weight reduction at the highest dose over 72 weeks. FDA-approved in 2022 (T2DM) and 2023 (obesity).
Type
GIP/GLP-1 dual agonist
Structure
39 aa, lipidated peptide (Eli Lilly)
Molecular weight
~4814 Da
Target area
T2DM, obesity
Storage
2–8°C (reconstituted)
Stability
~30 days (reconstituted)
Metabolic support
Glucose and lipid metabolism shift favorably: insulin sensitivity improves, glycemic swings and HbA1c drop, while LDL and triglycerides normalize. Body composition refines, fat mass decreases, lean mass is preserved or grows. Appetite is regulated both centrally and peripherally (GLP-1 / GIP / glucagon pathways), so caloric intake settles into a sustainable range without constant willpower. Energy expenditure and thermogenesis rise modestly.
Data console
Lab data
Research indications
Investigated uses and mechanisms
Weight regulation
Reduced appetite and increased energy expenditure via GLP-1 / GIP / glucagon agonism.
Type 2 diabetes
Improved insulin sensitivity and HbA1c reduction in clinical trials.
Cardiometabolic profile
Favorable shifts in lipid profile and blood pressure.
Reconstitution
How to prepare, step by step
Important
Sterile technique required. Use bacteriostatic water (BAC) only. Never distilled or tap water.
- 01
Remove the vial and bacteriostatic water (BAC) from refrigeration; let them reach room temp for 5 minutes.
- 02
Wipe both vial stoppers with an alcohol swab.
- 03
Draw 2 ml of BAC water into a sterile syringe (typical for the 5 mg vial).
- 04
Inject slowly down the side of the vial, do NOT spray directly onto the peptide powder.
- 05
Swirl gently in a circular motion until dissolved (~30 s), do not shake.
- 06
Wait for the solution to become clear. If sediment or discoloration appears, discard it.
- 07
Label the vial with reconstitution date and concentration.
- 08
Store at 2–8 °C, protected from light. Inspect visually before each use.
Quality indicators
How to recognize a pure peptide
Purity markers
4White / off-white powder
Typical appearance of sterile lyophilized peptide.
Comes with COA (Certificate of Analysis)
Independent lab analysis, ≥98% purity.
Intact, sealed vial
Rubber stopper + aluminum crimp intact, ensuring sterility.
Dissolves clear
Clear solution after reconstitution, no sediment.
Use caution
1Storage temperature
Extended room-temp exposure may reduce potency.
Do not use
2Discoloration / sediment
Yellow, cloudy or particulate solution, indicates degradation, do not use.
Damaged packaging
Cracked vial or loose cap, sterility compromised, discard.
Interactions & stacks
What to combine and what to avoid
Retatrutide
SynergisticTriple incretin agonist: metabolic health and weight loss
Tesamorelin
SynergisticGHRH analog: visceral fat reduction (FDA-approved)
Berberine
SynergisticInsulin sensitivity + GLP-1 effects combine well.
Vitamin C / Zinc / B-complex
SynergisticSupports collagen synthesis and antioxidant capacity.
Metformin
ComplementaryMany clinical protocols combine them, supervision advised.
Caffeine
Requires timingCompatible with morning dosing; avoid late-day stacking.
NSAIDs (Ibuprofen, ASA)
Use cautionLong-term concurrent use may blunt regenerative effects.
Alcohol
AvoidReduces recovery and increases side-effect risk.
Safety
Side effects, stop signs, contraindications
Side effects · 5
- Nausea, headache, especially during titration
- Appetite and bowel-motility shifts
- Local skin reaction at injection site
- Transient blood-sugar variability (esp. in diabetics)
- Mild heart-rate increase
Contraindications · 5
- Pregnancy and breastfeeding
- Active malignancy
- Known allergy to the peptide or its components
- Severe hepatic or renal impairment (medical consultation required)
- Age under 18
Related Peptides
Same therapeutic category
Studies
Related research and clinical findings
Tirzepatide as compared with semaglutide for obesity (SURMOUNT-5)
Aronne LJ, Horn DB, le Roux CW, et al.
After 72 weeks, tirzepatide −20.2% vs semaglutide −13.7% body weight reduction; ≥25% loss was roughly twice as common with tirzepatide.
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Over 72 weeks, the 15 mg dose achieved an average 22.5% body weight reduction with a favourable cardiometabolic profile.
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Wadden TA, Chao AM, Machineni S, et al.
After intensive lifestyle intervention, tirzepatide produced an additional 18.4% body-weight reduction over 72 weeks.
Telegram
Have a question about Tirzepatide?
Reach out to an advisor on Telegram. We can help you find the right peptide.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.